375. Or si Sanofi-Aventis France a

375. Or si Sanofi-Aventis France avait effectivement mis en ceuvre une strategie de communication globale et structuree demigrant les generiques concurrents et semant le doute parmi les
professionnels de sante comme l'affirme la Decision, on aurait dO, a tout le moins, observer un
mauvais demarrage de la generification. Mais c'est tout le contraire qui s'est passe : une penetration rapide et forte des generiques, sur un marche dont les autorites de concurrence s'accordent pour considerer que les premieres semaines sont decisives et « figent » souvent les dynamiques et les parts de marche.
376. Un tel constat confirme que le ralentissement observe ulterieurement n'est pas lie a
('information communiquee par Sanofi-Aventis France.

377. Ce n'est qu'a partir du mois d'avril 2010, soit trois mois apres la fin des pratiques, que I'evolution du taux de penetration des generiques s'est inflechie et que celui a commence a diminuer. Cette baisse a toutefois ete legere : il n'a diminue que de 0,4% entre mars et avril 2010 (de 69,3% a
68,9 %) et au total il a perdu 3,7 % entre son pie de mars 2010 et la fin de l'annee 2010 (de
69,3 % a 65,6 %).

378. Pour tenter d'expliquer la bonne progression du taux de generification pendant toute la periode des pratiques alleguees, la Decision avance une theorie selon laquelle l'information communiquee par Sanofi-Aventis France aurait ete « diffusee de far;on tres progressive », produisant ses effets
avec un decalage dans le temps de plusieurs mois199

379. Premierement, cette theorie pour le moins hasardeuse d'un soi-disant effet decale de la visite medicale ne releve que de la pure speculation et ne s'appuie sur aucun element concret.



199 Decision, pts. 555 a 564.

Résultats (Anglais) 1:

375. or if sanofi-aventis France had actually set ceuvre a comprehensive communication strategy and structured demigrant generic competitors and sowing doubt among health professionals
as stated in the decision, it would do, at the very least, observe a
bad startup of generics. but it is just the opposite has happened:rapid and strong penetration of generic, in a market with competition authorities agree to consider that the first few weeks are critical and "freeze" often dynamic and market shares.
376. such a finding confirms that the slowdown is not observed subsequently binds a
(information communicated by sanofi-aventis France.
377.it was not until the month of April 2010, three months after the end of practices that i'evolution rate of generic penetration is bent and that began to decrease. However, this decline was slight: it has decreased by 0.4% between March and April 2010 (69.3% to 68.9%
) and in total it lost 3.7% from its pie March 2010 and the end of the year 2010 (from
693% to 65.6%).
378. attempt to explain the good growth rate of generics throughout the period of Alleged practices, decision advance a theory that the information communicated by sanofi-aventis France would have been "far from diffusee, is very progressive," producing its
effects with a lag time of several mois199
379. firstly,this theory for the least risky of a so-called decale effect of the medical visit will notes that pure speculation and not based on any concrete element.



199 decision, pts. 555 to 564.

Résultats (Anglais) 2:

375 Gold if Sanofi-Aventis France had actually put in work an overall communication strategy and structured demigrant competing generics and sowing doubt amongst the
professionals of health as stated in the Decision, one would dO, at least, observe a
bad start of generics. But it is the contrary which goes: a quick and penetration of generics, on a market in which competition authorities agree to consider that the first weeks are decisives and 'freeze' often dynamics and shares market.
376. Such a finding confirmed that the slowdown is subsequently does not lie a
('information communiquee par Sanofi-Aventis France.

377.) This is that starting from the month of April 2010, three months after the end of practices, that I'evolution of the rate of penetration of generics has inflechie and than starts to reduce. This decrease however was light: it has decreased by 0.4 per cent between March and April 2010 (69.3%
68, 9%) and total lost 3.7% between its pie of March 2010 and the end of the year 2010 (from
69,)3% to 65.6%).

378. To try to explain the good progress of the rate of generics for the duration of the alleged practices, Decision advances a theory that the information communicated by Sanofi-Aventis France would have been "broadcast far; it very progressive", producing its effects
with a lag time of several mois199

379. First, This theory for the less risky of a so-called medical visit décalé effect not noted that's pure speculation and not based on anything concrete.


199 Decision, pts. 555 a 564.

Résultats (Anglais) 3:

375. However if Sanofi-Aventis France had actually placed in d eveloping a comprehensive communication strategy and structured demigrant the generic competitors and sowing the seeds of doubt among the
health professionals as stated in the Decision, we would do, at the very least, observe a
bad start of the generification. But it is quite the opposite happened:A rapid penetration and strong of generics, on a market in which the competition authorities agree to consider that the first weeks are decisive and "freeze" often the dynamic and market shares.
376. Such an observation confirmed that the observed slowdown later is not bound a
( 'information communicated by Sanofi-Aventis France.

377.It is only starting from the month of April 2010, three months after the end of the practices, that I'evolution of the rate of penetration of generics has shifted and that the one has begun to decrease. This decline, however, was slight: it has decreased by only 0.4 per cent between March and April 2010 (from 69.3 per cent a
68.9 %) and in total he has lost 3.7 per cent between its pius of March 2010 and the end of 2010 (to
69,3 % Has 65.6 % ) .

378. To try to explain the good progress of the rate of generification throughout the period of the alleged practices, the Decision advanced a theory according to which the information communicated by Sanofi-Aventis France would have been " broadcast of far;it very progressive ", producing its effects
with a time-lag of several months199

379. First,This theory for the least risky of a so-called delayed effect of the medical visit is accountable only to the pure speculation and is not supported on any concrete element.



199 Decision, pts. 555 A 564.